Denimal Damien, Ménégaut Louise, Rossi Cédric, Duvillard Laurence, Masson David
Department of Biochemistry, University Hospital Centre Dijon-Burgundy, France.
Department of Clinical Hematology, University Hospital Centre Dijon-Burgundy, France.
Biochem Med (Zagreb). 2016;26(2):255-9. doi: 10.11613/BM.2016.029.
Major hyperferritinemia is a rare feature in clinical laboratories associated with a wide variety of disorders, including hemophagocytic lymphohistiocytosis (HLH). The diagnosis of HLH is based on clinical and biological criteria, such as those proposed by the Histiocyte Society. However, several of these criteria are not relevant in the specific setting of hematologic malignancies.
A 69-year-old male was treated for an acute myeloid leukaemia. On day 15 after the start of chemotherapy, he developed severe sepsis with high fever, low blood pressure and hepatosplenomegaly.
Blood tests were marked by extreme hyperferritinemia (191,000 µg/L, reference range: 26-388 µg/L) with increased C-reactive protein (87.0 mg/L) and procalcitonin (1.94 µg/L) and aspartate aminotransferase (499 U/L 37 °C) in the setting of chemotherapy-induced aplasia. This unusual extreme ferritinemia led to suspect HLH triggered by an invasive infection. Under intensive treatment, the clinical status improved and ferritin levels significantly decreased.
The diagnosis of HLH is usually based on clinical and biological criteria, mainly fever, splenomegaly, cytopenias, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis and hyperferritinemia. In this patient, the diagnosis of HLH was challenging because several criteria, such as hypertriglyceridemia, hemophagocytosis and hypofibrinogenemia, were absent. In addition, some criteria of HLH are not relevant in the setting of hematologic malignancy, in which fever, splenomegaly, cytopenias and elevated lactate dehydrogenase are commonly observed independently of HLH. This unusual case of extremely high ferritinemia emphasizes the important weight of the ferritin level for the diagnosis of HLH in adult patients in the setting of hematologic malignancies.
严重高铁蛋白血症是临床实验室中一种罕见的特征,与多种疾病相关,包括噬血细胞性淋巴组织细胞增生症(HLH)。HLH的诊断基于临床和生物学标准,如组织细胞协会提出的标准。然而,其中一些标准在血液系统恶性肿瘤的特定情况下并不适用。
一名69岁男性因急性髓系白血病接受治疗。化疗开始后第15天,他出现了严重脓毒症,伴有高热、低血压和肝脾肿大。
血液检查显示极度高铁蛋白血症(191,000µg/L,参考范围:26 - 388µg/L),同时在化疗诱导的再生障碍性贫血背景下,C反应蛋白(87.0mg/L)、降钙素原(1.94µg/L)和天冬氨酸转氨酶(499U/L 37°C)升高。这种异常的极高铁蛋白血症导致怀疑由侵袭性感染引发HLH。在强化治疗下,临床状况改善,铁蛋白水平显著下降。
HLH的诊断通常基于临床和生物学标准,主要包括发热、脾肿大、血细胞减少、高甘油三酯血症、低纤维蛋白原血症、噬血细胞现象和高铁蛋白血症。在该患者中,HLH的诊断具有挑战性,因为缺少一些标准,如高甘油三酯血症、噬血细胞现象和低纤维蛋白原血症。此外,HLH的一些标准在血液系统恶性肿瘤情况下并不适用,在这种情况下,发热、脾肿大、血细胞减少和乳酸脱氢酶升高通常独立于HLH而出现。这个极高铁蛋白血症的罕见病例强调了铁蛋白水平在血液系统恶性肿瘤成年患者HLH诊断中的重要权重。